News | April 03, 2025
Asahi Kasei Life Science begins operation
Being a premium partner for pharmaceutical companies by contributing to safety and productivity of pharmaceutical manufacture
Being a premium partner for pharmaceutical companies by contributing to safety and productivity of pharmaceutical manufacture
Subcutaneous pembrolizumab administered every six weeks with a median injection time of two minutes, in combination with chemotherapy, shows consistent results across reported efficacy and safety endpoints compared to IV KEYTRUDA in combination with chemotherapy
Dupixent (dupilumab) approved as the first-ever biologic medicine in Japan for patients with Chronic Obstructive Pulmonary Disease (COPD)
EC decision marks the fourth approval for CAPVAXIVE for pneumococcal vaccination in adults
PCC has secured the commercialization rights for the EU, UK, and Norway and will be responsible for distributing Neoatricon in these regions
Finerenone is the first drug targeting the mineralocorticoid receptor (MR) pathway to demonstrate cardiovascular benefits in a Phase III study in patients with heart failure
Nipaguard SCE Vita delivers comprehensive antimicrobial protection for personal care formulations
Talicia is also approved and launched in the UAE and additional countries may accept UK MHRA approvals as a reference for their own marketing approval processes
Empagliflozin and its Fixed Drug Combinations (FDCs) have been launched under the brand names Glempa, Glempa –L and Glempa-M
The MDR certification reafirms that these products meet the highest safety, quality, and regulatory standards
Subscribe To Our Newsletter & Stay Updated
